English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Bevacizumab has shown survival benefits when added to chemotherapy in patients with metastatic colon cancer (mCRC). However, the efficacy of bevacizumab may depend on the accompanying chemotherapeutic regimen. We performed this meta-analysis to examine the impact of the choice of chemotherapy regimen on the survival benefits of bevacizumab in the first-line treatment for patients with mCRC. Electric databases were searched for eligible randomized trials. From 9 studies, 3,710 patients with mCRC were included in the meta-analysis of hazard ratios (HRs) for progression-free survival (PFS) or overall survival (OS). Compared with chemotherapy alone, the addition of bevacizumab to chemotherapy significantly prolonged PFS (HR = 0.66 [95% confidence interval (CI), 0.55-0.77], P &lt; 0.0001) and OS (HR = 0.84 [95% CI, 0.77-0.92], P = 0.0001). In the subgroup analysis according to the chemotherapeutic regimens, bevacizumab showed both PFS (HR = 0.57 [95% CI, 0.41-0.77], P = 0.0004) and OS (HR = 0.79 [95% CI, 0.67-0.93], P = 0.004) advantages only in combination with irinotecan-based regimen. In conclusion, this meta-analysis confirms that the addition of bevacizumab to chemotherapy significantly prolongs PFS and OS in the first-line treatment for mCRC. The subgroup analyses suggest that irinotecan-based regimen may be a better partner of bevacizumab in terms of both PFS and OS.

The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials